Meeting
2020 ASCO Virtual Scientific Program
Risk of secondary hematologic malignancies in patients with ovarian cancer treated with PARP inhibitors: A combined meta-analysis of seven phase III randomized controlled trials.
Authors
Thura Htut
Department of Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, United Kingdom
Thura Htut , Somedeb Ball , Sriman Swarup , Anita Sultan , Myat M. Han , Yin Mon Myat , Fred L. Hardwicke , Lukman Aderoju Tijani , Kyaw Thein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12076)
DOI
10.1200/JCO.2020.38.15_suppl.12076
Abstract #
12076
Poster Bd #
364
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
First Author: Myo Zaw
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Discontinuation of poly(adenosine diphosphate-ribose) polymerase inhibitors due to adverse events in patients with recurrent ovarian cancer: A meta-analysis of three phase III trials.
First Author: Kyaw Zin Thein
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Risk of health-related quality-of-life events and pulmonary toxicities in patients with cancer treated with poly adenosine diphosphate ribose polymerase inhibitors: A meta-analysis of seven phase III trials.
First Author: Sriman Swarup
Poster
2022 ASCO Annual Meeting
Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer.
First Author: David M. O'Malley